Dyne Therapeutics (DYN) announced that it has commenced an underwritten public offering of $200M of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics initiated with a Buy at JonesResearch
- Dyne Therapeutics initiated with a Market Perform at Bernstein
- Dyne Therapeutics price target lowered to $32 from $46 at Baird
- Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating
- Dyne Therapeutics’ DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials